Sanofi gets EMA panel recommendation for Dupixent to treat eosinophilic esophagitis Ruchika Sharma19 Dec 2022 10:30 AM ISTEoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly.
Sanofi Dupixent gets European Commission nod for Prurigo Nodularis Ruchika Sharma18 Dec 2022 5:30 PM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Commission (EC) has expanded the marketing authorization for...
Britain regulator calls for review of reactions in eyes to Sanofi asthma drug Dupixent Ruchika Sharma30 Nov 2022 5:30 PM ISTEuropean and U.S. health regulators have listed conjunctivitis, an eye irritation that can cause redness and discomfort, as a side effect of Dupixent
Sanofi Dupixent recommended for EU approval by CHMP for prurigo nodularis treatment Ruchika Sharma13 Nov 2022 4:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not...
Sanofi forecasts faster profit growth on Dupixent, flu vaccine demand Ruchika Sharma30 Oct 2022 10:00 AM ISTParis: French drugmaker Sanofi on Friday forecasted faster earnings growth this year on strong demand for its bestselling drug Dupixent and for...
FDA approves dupilumab as first and only treatment Indicated for Prurigo Nodularis Dr. Kamal Kant Kohli2 Oct 2022 7:30 PM ISTPrurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest...
Sanofi Prurigo nodularis drug Dupixent gets USFDA okay Ruchika Sharma30 Sept 2022 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (USFDA) has approved Dupixent (dupilumab) for the treatment of adult patients...
Dupilumab significantly improves skin lesions and itching among treated patients with prurigo nodularis Dr. Kamal Kant Kohli21 Sept 2022 8:00 PM ISTDupilumab improves skin lesions and itching among treated patients with prurigo nodularis, reveals Initrial data presented at the European Academy of...
Sanofi, Regeneron Pharma announce positive Phase 3 data for Dupixent in adults with uncontrolled prurigo nodularis Ruchika Sharma10 Sept 2022 12:56 PM ISTPeople with prurigo nodularis experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.
Sanofi Dupixent Phase 3 trial shows positive results in children with eosinophilic esophagitis as young as age 1 Ruchika Sharma16 July 2022 12:30 PM ISTEoE is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.
FDA approves dupilumab for treatment of atopic dermatitis in pediatric patients Dr. Kamal Kant Kohli10 Jun 2022 9:00 AM ISTTARRYTOWN, N.Y. and PARIS: The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for children aged 6 months to 5 years with...
Sanofi Dupixent wins USFDA nod for atopic dermatitis Ruchika Sharma8 Jun 2022 1:00 PM ISTDupixent is administered as an injection under the skin (subcutaneous injection) at different injection sites.
